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In Brief
We established a robust capil-
lary-flow data-independent ac-
quisition MS platform capable of
measuring 31 plasma proteomes
per day without the need of re-
peated acquisition of the same
sample. We acquired 1508 sam-
ples of the DiOGenes study
(multicentered, Europa-wide ca-
loric restriction weight loss and
maintenance study of overweight
and obese, non-diabetic partici-
pants). This was achieved using
a single analytical column. Com-
prehensive biological reactions
to weight loss and maintenance
were observed.
Graphical Abstract
Highlights
• Robust capillary-flow DIA was established at 31 clinical samples per day.
• 1508 samples of dietary intervention study DiOGenes were measured on a single column.
• Comprehensive biological reactions to weight loss and maintenance were observed.
• Comparison to independent studies shows high reproducibility of potential biomarkers.
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Analysis of 1508 Plasma Samples by Capillary-
Flow Data-Independent Acquisition Profiles
Proteomics of Weight Loss and Maintenance*□S
Roland Bruderer‡, Jan Muntel‡, Sebastian Mu¨ller‡, Oliver M. Bernhardt‡,
Tejas Gandhi‡, Ornella Cominetti§, Charlotte Macron§, Je´roˆme Carayol§,
Oliver Rinner‡, Arne Astrup¶, Wim H.M. Saris, Jo¨rg Hager§, Armand Valsesia§,
Loïc Dayon§, and Lukas Reiter‡**
Comprehensive, high throughput analysis of the plasma
proteome has the potential to enable holistic analysis of
the health state of an individual. Based on our own expe-
rience and the evaluation of recent large-scale plasma
mass spectrometry (MS) based proteomic studies, we
identified two outstanding challenges: slow and delicate
nano-flow liquid chromatography (LC) and irreproducibil-
ity of identification of data-dependent acquisition (DDA).
We determined an optimal solution reducing these limita-
tions with robust capillary-flow data-independent acqui-
sition (DIA) MS. This platform can measure 31 plasma
proteomes per day. Using this setup, we acquired a large-
scale plasma study of the diet, obesity and genes dietary
(DiOGenes) comprising 1508 samples. Proving the robust-
ness, the complete acquisition was achieved on a single
analytical column. Totally, 565 proteins (459 identified with
two or more peptide sequences) were profiled with 74%
data set completeness. On average 408 proteins (5246
peptides) were identified per acquisition (319 proteins in
90% of all acquisitions). The workflow reproducibility was
assessed using 34 quality control pools acquired at reg-
ular intervals, resulting in 92% data set completeness with
CVs for protein measurements of 10.9%.
The profiles of 20 apolipoproteins could be profiled re-
vealing distinct changes. The weight loss and weight main-
tenance resulted in sustained effects on low-grade inflam-
mation, as well as steroid hormone and lipid metabolism,
indicating beneficial effects. Comparison to other large-
scale plasma weight loss studies demonstrated high ro-
bustness and quality of biomarker candidates identified.
Tracking of nonenzymatic glycation indicated a delayed,
slight reduction of glycation in the weight maintenance
phase. Using stable-isotope-references, we could directly
and absolutely quantify 60 proteins in the DIA.
In conclusion, we present herein the first large-scale
plasma DIA study and one of the largest clinical research
proteomic studies to date. Application of this fast and
robust workflow has great potential to advance biomarker
discovery in plasma. Molecular & Cellular Proteomics
18: 1242–1254, 2019. DOI: 10.1074/mcp.RA118.001288.
The circulatory system is the primary link between all parts
of the body in both humans and animals. As such, it harbors
the potential to indicate the health status of any key organ.
Blood delivers necessary substances such as nutrients and
oxygen to cells and transports metabolic waste products
away from those same cells. It is also vital to the immune
system-based host defense mechanisms. Blood consists of
cells suspended in a liquid called plasma (1). Blood is well
suited for diagnoses based on biomarkers, because it is read-
ily obtainable with minimally invasive and repeatable sampling
and large biobanks exist for retrospective analyses.
Up to now, 3500 to 5000 proteins have been measured in
plasma or serum (2, 3). In addition, there are good arguments
that all human proteins might be present in plasma to a certain
extent given that blood flows through almost all organs of our
body. However, not many more than 100 protein biomarkers
from plasma have been cleared/approved by the Food and
Drug Administration (FDA)1 (4). This contrasts with the high
number of protein biomarker studies performed (5). This fact
indicates that is difficult to find, validate, and translate new
disease or health biomarkers in plasma.
Biomarker discovery has proven to be a complicated, mul-
tistage process. Specifically, in proteomics, many biomarker
candidates have been generated, but only a few could be
validated, and even fewer are used today in the clinic. Poten-
tial causes for this are inappropriate study design, limited
sample sizes (e.g. large interindividual variations were under-
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estimated or technological hurdles to measuring large sample
sets) and poor sample quality (5–7). Because of the large
individual heterogeneity observed in plasma proteomics (e.g.
from age, sex, ethnicity and lifestyle), the typical number of
samples per condition could be more than a hundred to
ensure enough statistical power (8).
A field where these above-mentioned difficulties apply is
weight loss studies. Obesity is a medical condition affecting
large parts of the population worldwide and is rising rapidly in
many places (9, 10). Excess of fat negatively impacts health
and can lead to multiple comorbidities including cardiovas-
cular and endocrine diseases such as diabetes, or cancer. It is
not fully understood how excess fat manifests its negative
effects for the body and how differences occur between indi-
viduals (11). Obesity related metabolites are clearly detectable
in plasma including fatty acids in lipoproteins and increased
chronic inflammation is observed (e.g. higher C-reactive protein
levels) (12, 13). Obesity can be addressed by prevention (phys-
ical activity, nutrition and behavioral changes) and medical
treatment but there remains an unmet need for both better
treatment options and early diagnosis of obesity’s comorbidi-
ties. To date, medication that controls appetite has had little
success because of adverse side effects and possibly also large
inter-person variability in response.
To advance the understanding of obesity, the European-
wide weight loss and maintenance study called DiOGenes
was initiated (http://www.diogenes-eu.org) (14, 15). The hun-
dreds of participants were overweight or obese people (body
mass index (BMI)27). Eight weeks of weight loss during a low
caloric diet (800 kcalday-1 over 8 weeks) were followed by 6
months of weight maintenance (with an extra six months for the
two leading centers). The study was performed in eight loca-
tions in Europe. Because of its controlled design and large
sample numbers, the DiOGenes study has the potential to lay
the foundation for personalized nutrition and dietary interven-
tion.
To perform successful protein biomarker discovery exper-
iments with large enough sample cohorts, mass spectrometry
(MS)-based proteomics is in principle, well suited. The tech-
nological ability of MS-based proteomics has drastically im-
proved over the last several years (16–19). Currently, the MS
biomarker discovery approach has several key features that
could render it the preferred platform for protein biomarker
discovery, namely its high specificity, protein coverage and
the accessibility of PTMs. Historically, MS-based proteomics
has not been used in biomarker discovery studies, where
large numbers of samples are routinely measured. Recently,
several large-scale plasma MS studies were performed by Liu
et al. (342 proteomes of 342 samples) (20), Cominetti et al.
(1000 proteomes in 300 TMT experiments of 1000 samples)
(21) and Geyer et al. (1276 proteomes of 319 samples) (22).
Common to all three of these studies is that they used nano-
flow liquid chromatography (LC), which generates long injec-
tion-to-injection overheads. Cominetti et al. performed deple-
tion of abundant plasma proteins with concatenated isobaric
labeling experiments, rendering the experiments expensive and
sensitive to sample preparation performance (23), whereas less
prone to nano-LC instabilities. Additionally, the use of data-de-
pendent acquisition (DDA) mode generates sparse datasets
with irreproducible sampling of the peptides in the sample (24),
making statistical analysis more difficult and reducing the power
of the large sample numbers. To reduce this problem of DDA,
multiple re-injections of the same sample were performed (12,
21). From this study, we concluded that two main challenges
that remain to be addressed are reproducible MS acquisition
and fast, robust chromatography.
The recently established versions of data-independent ac-
quisition (DIA) achieved excellent reproducibility at high cov-
erages making multiple sample re-injections obsolete (24, 25).
Additionally, an 10-fold higher flow rate LC has been shown
to be more robust and reproducible than nano-flow LC (26,
27) and was shown to be compatible with DIA (27, 28). There-
fore, we combined higher flow LC with DIA MS in this study.
Herein, we demonstrate the ability to profile 1,508 plasma
proteomes from the DiOGenes weight loss and maintenance
study with a label-free, single shot DIA and robust capillary
flow chromatography approach. At a rate of 31 samples per
day, we were able to identify and quantify 565 proteins with
high reproducibility, with 459 proteins being identified with
two or more peptide sequences per protein (data set com-
pleteness of 74%) and on average 408 proteins (5246 peptide
sequences) per acquisition. We found proteins and pathways
consistently altered after weight loss and during the mainte-
nance phase. Comparison to related and unrelated studies of
weight loss clearly demonstrated the general validity of biolog-
ical findings obtained with large-scale plasma proteomic exper-
iments. Therefore, we anticipate a high impact of the capillary
flow DIA large-scale proteomic method in clinical research.
EXPERIMENTAL PROCEDURES
Ethics—The studies were performed in agreement with the Helsinki
declaration and approved by local ethical committees in the respec-
tive countries: the Medical Ethics Committee of the University Hos-
pital Maastricht and Maastricht University, the Netherlands (NL); the
Committees on Biomedical Research Ethics for the Capital region of
Denmark, Denmark (DK); the Suffolk Local Research Ethics Commit-
tee, United Kingdom; the University of Crete Ethics Committee,
Greece; the Ethics Commission of the University of Potsdam (Ger-
many); the Research Ethics Committee at the University of Navarra,
Spain; the Ethical Committee of the Institute of Endocrinology, Czech
Republic; and the Ethical Committee to the National Transport Mul-
tiprofile Hospital in Sofia, Bulgaria. The Cantonal Ethics Committee
for Research on Human Beings, Vaud, Switzerland approved the
1 The abbreviations used are: FDA, Food and Drug Administration;
CV, coefficient of variation; DDA, data-dependent acquisition; DIA, da-
ta-independent acquisition; FDR, false discovery rate; MS1, peptide
precursor survey scan; MS2, fragment ion scan; CID, clinical investiga-
tion day; LCD, low-calorie diet; WMD, weight maintenance diet; SIS,
stable isotope standard; LC, liquid chromatography; RF, radio frequen-
cy; MS, mass spectrometry, PTM, post-translational Modification.
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study protocol to be performed. All study participants signed an
informed consent document after verbal and written instructions, and
according to local legislation. The Cantonal Ethics Committee for
Research on Human Beings, Vaud, Switzerland approved the study
protocol to be performed by Biognosys (Schlieren, Switzerland).
Study Design—DiOGenes is a multicenter, randomized controlled
dietary intervention study, involving eight European countries (15).
Briefly, 938 overweight/obese, non-diabetic, adults (BMI between 27
and 45 kg/m2, blood fasting glucose below 6.1 mmol/L) underwent an
8-week weight loss phase using a complete meal replacement low
calorie diet (LCD). The LCD provided 800 kcal/day (Modifast from
Nutrition et Sante´, Revel, France). Among the 781 participants who
completed the LCD phase, 773 achieved  8% weight loss and were
randomized to a 26-week weight maintenance diet. A total of 548
subjects completed the 6-month weight maintenance diet (WMD)
phase. By study design, the two leading intervention centers (DK and
NL) continued the WMD for an additional 26-weeks. This design led to
a large plasma sample collection (n  1508) available at different
clinical intervention day (CID): CID1 corresponding to baseline, CID2
to the LCD termination, CID3 to the 26-week WMD termination and
CID4 to the 52-week WMD termination (14).
Materials—Iodoacetamide, tris(2-carboxyethyl)phosphine, trifluo-
roacetic acid, formic acid, ammonium formate, acetonitrile, HPLC
water, ammonium bicarbonate, and urea were purchased from
SIGMA-Aldrich (Munich, Germany), trypsin sequencing grade from
Promega (Madison, WI), PlasmaDeepDive kit from Biognosys.
Sample Preparation—1508 human plasma samples were obtained
from the European DiOGenes project (14). They were thawed again
directly before the preparation for proteomic analysis. The DiOGenes
sample set was randomized over 17 96-well plates (supplemental Fig.
S1). Each plate contained four pooled plasma samples (twice CID1
and twice CID3 pools) that were prepared together with the other
samples. The plasma samples were prepared with the Sample Prep-
aration Kit Pro (Biognosys). In brief, volumes of 10 l plasma were
mixed with 90 l of denaturation buffer, reduced at 37 °C for 30 min
followed by alkylation in the dark for 30 min. Then, 15 l of denatured
plasma were mixed with ammonium bicarbonate buffer and 2 g
of trypsin. Digestion was performed at 37 °C for 3 h and stopped
with the digestion stop solution. Desalting was performed using
MacroSpin C18 96-well plates (The Nest Group, Southborough,
MA) following the manufacturer’s instructions. For the DIA analysis,
dried samples were resuspended in 50 l LC of solution A contain-
ing iRT and PlasmaDeepDive kits. Finally, the plates were centri-
fuged at 14,000  g at 4 °C for 30 min, prior to acquisition. The
samples were then transferred to 96-well ACQUITY UPLC 700 l
sample plates (Waters, Milford, MA).
High pH Reversed Phase Fractionation—For library generation,
pooled samples from all samples were fractionated using high pH
reversed-phase (HPRP) chromatography. 200 g of the digest was
adjusted to pH 10 using 0.2 M ammonium formate. Next, each sample
was fractionated using HPRP separation on a Dionex UHPLC
(Thermo Scientific, Waltham, MA) with a 2.1150 mm ACQUITY
UPLC CSH C18 1.7 m column (Waters) at 60 °C with 0.3 ml/min flow
rate and a 30 min gradient with buffer A (20 mM ammonium formate
and buffer B acetonitrile, see supplemental Table S1); 1 min micro-
fractions were pooled into 15 fractions using fraction pooling.
Plasma Capillary Flow DIA Setup Establishment—An Orbitrap Fu-
sion Lumos (Thermo Scientific) was connected to an ACQUITY M-
Class (Waters) using Acquity M-Class UPLC CSH 1.7 m  15 cm
columns (Waters) and Easy Transfer lines (Thermo Scientific) for
electrospray (supplemental Fig. S2A). The following parameters were
identified and optimized as relevant parameters influencing the per-
formance of identification and quantification and robustness: gradient
length, column length and diameter, flow, emitter tip type and size,
sample amount loaded, electrospray current and transfer tube tem-
perature. Reversed-phase columns of different inner diameters (75,
150, and 300 m) were tested. All three sized columns performed
similarly in terms of identification and quantification performance for
the gradient lengths relevant for this study (up to 60 min). Therefore,
300 m ID columns were chosen because they were more robust
when separating plasma samples. Up to date we did not observe any
column clogging on the 300 m ID column in our laboratory and the
columns lasted typically 2,000 injections (5 columns, back pressure
increase of about 14%). Optimized DIA methods were generated for
the different gradient methods as described in (25). A gradient length
of 40 min resulted in 97% of the identifications possible on that setup
(judged for gradients from 5 to 60 min) (supplemental Fig. S2B). A flow
rate of 5 l/min for a gradient of 40 min resulted in 13% overhead
from injection to injection (i.e. 6 min) (supplemental Fig. S2C and
S2D). A sample load of 5 g resulted in the maximum number of
identified and quantified proteins (supplemental Fig. S2E). In sum-
mary, this setup enabled the acquisition of 31 samples per day in a
reproducible, sensitive and robust manner.
Mass Spectrometric Acquisition of the DiOGenes Sample Set—For
the capillary flow LC-MS setup, 5 g of each plasma sample was
analyzed using one column setup with an ACQUITY UPLC M-class
CSH C18 1.7 m column of 300 m150 mm dimensions (Waters) at
50 °C on an ACQUITY UPLC M-class system (Waters) connected to
an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Scien-
tific). A capillary flow Easy-spray transfer line (20 m) was used with
an Easy- Spray source (Thermo Scientific). The peptides were sepa-
rated with a 40 min segmented gradient (supplemental Table S2). The
flow rate was 5 l/min. The solvents were A: 1% acetonitrile and 0.1%
formic acid in water and B: 85% acetonitrile and 0.1% formic acid in
water. “Loop” was set to partial with offline after 1.1 min. The seal
wash was 90 min and run time was set to 45 min. Following MS
parameter were used. The RF lens frequency was set to 40%, the
spray voltage was set to 3 kV, the ion transfer tube was set to 300 °C
and the internal calibration was used with ion 445.12003 m/z. For
DDA, the quadrupole isolation width was set to 1.6 m/z. The method
cycle time was set to 3 s. The full scan was performed between
350–1650 m/z at 60 k resolution (AGC target of 1  106 or 20 ms
injection time). HCD fragmentation was set to normalized collision
energy of 27%. The dependent MS2 scans were recorded at 30k
resolution with an AGC of 2  105 and a max. fill time of 50 ms. The
first mass was fixed at 120 m/z. The intensity threshold was set to 5
104, charge states 2–5 were included and the dynamic exclusion was
set to 10 s with 25 ppm mass tolerance and isotopes were excluded.
The DIA method consisted of a MS1 scan from 350 to 1650 m/z at
120 k resolution (AGC target of 1 106 or 20 ms injection time). Then,
33 DIA segments were acquired at 30 k resolution with an AGC target
1  106 and 55 ms for maximal injection time (supplemental Table
S3). The setting “inject ions for all available parallelizable time” was
enabled. HCD fragmentation was set to normalized collision energy of
27%. The spectra were recorded in profile mode. The default charge
state for the MS2 was set to 3.
During the acquisition of the first four plates of the DiOGenes
sample set, a failure of the cooling of the MS facility occurred and was
not fixed until the end of plate 6. For that reason, two plates were
reacquired at the end of the whole sequence. The mass spectrometer
was recalibrated after plates 6 and 10. During plate 8, the ion funnel
of the Orbitrap Fusion Lumos was cleaned.
Mass Spectrometric Data Analysis—To perform Tier 3 analyses
(29), DIA spectra were analyzed with Spectronaut Pulsar X
12.0.20491.6 (24). The default settings were used. In brief, retention
time prediction type was set to dynamic iRT (adapted variable iRT
extraction width for varying iRT precision during the gradient) and
correction factor for window 1. Mass calibration was set to local mass
Capillary Flow DIA on DiOGenes Study
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calibration. Interference correction on MS1 and MS2 level was en-
abled. The algorithm is based on correlation of extracted ion currents
to a consensus elution profile (24). The false discovery rate (FDR) was
estimated with the mProphet approach (30) and set to 1% at peptide
precursor level and 1% at protein level (31).
The DDA spectra were analyzed with the MaxQuant (Version
1.6.0.1) software (32) with default settings using the Andromeda
search engine (33). Digestion enzyme specificity was set to Trypsin/P.
Search criteria included carbamidomethylation of cysteine as a fixed
modification, oxidation of methionine and acetyl (protein N terminus)
as variable modifications. Allowing up to 2 missed cleavages. The
initial mass tolerance for the precursor was 4.5 ppm and for the
fragment ions was 20 ppm. The DDA files were searched against
the human UniProt fasta database (state 1st July 2017, 42,223 en-
tries) and the Biognosys’ iRT peptides fasta database (uploaded to
the public repository). For a global post translational modification
analysis, we searched the DDA data with MetaMorpheus (V.0.0.297)
(34). The default settings were applied, and Hex modifications were
added. For targeted glycation DIA analysis, a Maxquant search with
the variable modifications of K,R and protein N-terminal glycation by
C6H10O5 (162.0528 Da) was executed. Peptides with localization
probability 0.75 were removed. The libraries were generated using
the library generation functionality of Spectronaut with default
settings.
Term Usage Definition—When we use the term peptides in this
study, we refer to peptide precursors. When we use proteins, we refer
to protein groups as determined by the ID picker algorithm (35) and
implemented in Spectronaut. Proteins were counted as single hit
identification, if they were identified by precursors derived from a
single peptide sequence.
Experimental Design and Statistical Rationale—For the analysis of
intra individual coefficients of variation (CVs), only individuals having
been sampled on all 4 CIDs were considered; for the inter individual
CV calculation samples from all 4 CIDs, 4 different, random individ-
uals were combined (resulting in a CV based on four samples for both
analyses). For batch effect correction we used batch mean centering
(36). Statistical pairwise condition comparison analysis on protein
level was performed using Welch’s t test (paired, the null hypothesis
is no change, mean   0, two sided, not assuming equal variance).
The p values were corrected for multiple testing using the q-value
approach to control the overall FDR (37). Data were interpreted using
Qiagen’s Ingenuity® Pathway Analysis (IPA®, Qiagen Redwood City,
Hilden, Germany) using all identified proteins as the background
dataset, Fisher’s exact test right-tailed and p values were adjusted by
the Benjamini-Hochberg approach. Unsupervised clustering was per-
formed using Manhattan distance and Ward’s clustering algorithm. To
assess differential abundance of PTMs the fold change of the signif-
icantly differential abundant PTMs were corrected by the change of
the global protein.
RESULTS
Establishment and Characterization of a Robust Capillary
Flow DIA Setup—In order to acquire the proteomes of 1508
plasma samples, we developed a robust and high-perform-
ance LC-MS workflow. Higher flow rate LC makes it more
robust and results in shorter gradient overheads, therefore we
evaluated capillary flow, which promised a balance between
performance and robustness. We selected the Orbitrap Fu-
sion Lumos because of its robust ion source and its excellent
performance in both DIA and DDA. The ACQUITY M-Class
was chosen for its robustness, high flow capabilities and
excellent low LC-MS overhead times. After optimization steps
(supplemental Fig. S2), we evaluated the capillary flow DIA
setup. Therefore, we analyzed ten replicate injections of a
plasma pool prepared using an optimized plasma sample
preparation protocol (40 min gradient, 5 l/min and 5 g
injection; see Methods). For the targeted analysis from DIA,
we generated a library for the plasma pool based on 15 HPRP
fractions using DDA (8,641 peptide sequences from 661
proteins).
This experiment resulted in the cumulative quantification of
465 proteins (Sept. 2017 Uniprot Fasta with combined, cu-
rated immunoglobulins) (Fig. 1A). In total, 404/465 (87%) of
the proteins were quantified with CVs below 20% in the ten
repeated injections. Overall, we observed low CV values (with
median CV for all 465 proteins 5.2% and IQR 10.7%; see
Fig. 1B). The reproducibility of identification was very good
with less than 1% missing values, and with all 465 proteins
consistently quantified in more than two-thirds of the 10
LC-MS runs (Fig. 1C). Investigating the list of described
plasma proteins, we detected proteins covering nearly 6 or-
ders of magnitude (Fig. 1D).
Next, we aimed to assess quantification of well-established
biomarkers. Using the 10 technical replicates mentioned
above of a pooled plasma sample, we quantified FDA-cleared
or FDA-approved protein biomarkers, as listed by Anderson
(38). 47 out of the 52 identified FDA-approved biomarkers
were quantified with CVs at protein level of less than 20%
(Fig. 1E).
DiOGenes Study Description and Sample Preparation—
Having optimized and thoroughly tested the capillary flow
setup, we started with the acquisition of samples from the
multi-centered human dietary intervention study DiOGenes
(Fig. 2A). Totally, 1576 plasma samples were prepared,
comprised of 1508 individual samples and 68 pools. To
enable (label-free) absolute quantification, the stable iso-
tope standard (SIS) peptides for 100 plasma proteins of the
PlasmaDeepDive kit were added to the digests.
Acquisition of the DiOGenes Study of over 1800 Acquisi-
tions on a Single Analytical Reversed Phase Column—The
1576 DiOGenes samples were acquired using the above-
described LC-MS setup. Importantly, the whole acquisition
sequence was performed on a single analytical column
(totally 1803 runs for this manuscript including DDA, DIA
and re-injections). The retention time variability for the iRT
peptides was low (1.7% CV) and no systematic shift was
observed (slope 0.0009). We did not observe a single col-
umn blocking in the laboratory. The LC showed some fluc-
tuations during a cooling failure period of the MS-facility
and recovered thereafter. Importantly, this had no effect on
the acquisition performance as judged by the stable number
of protein identifications (supplemental Fig. S3). Intensity,
mass calibration and protein identifications per acquisition
remained stable over the acquisition sequence. Nonethe-
less, exploratory, unsupervised clustering analysis of the
data set revealed a batch effect between the acquisitions
Capillary Flow DIA on DiOGenes Study
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performed before and after the MS-facility cooling failure
period (supplemental Fig. S4A). Batch mean-centering was
performed using the reference pools (supplemental Fig.
S4B). Because the conditions were evenly randomized over
all 96-well plates, no confounding of biological conditions
and batches was present.
To be able to retrospectively monitor the performance
and reproducibility of the sample preparation and LC-MS
acquisition, pooled samples were added into all 17 96-well
plates and treated in the same manner as the DiOGenes
study samples (Fig. 2B). The CID1-pools showed 92% data
completeness (pooled samples collected at CID1, two such
pools were present on each of the 96-well plates) (Fig. 2C);
314 proteins were identified in all pool acquisitions (supple-
mental Fig. S5A) and the CVs for these proteins averaged
10.9% (Fig. 2D; 12.9% without batch correction). Similar
results were obtained from the CID3-pools (data not
shown).
The complete DiOGenes data set was analyzed and 72
LC-MS acquisitions with low protein identifications (below
330 protein identifications) were reinjected. Thereafter, 32
samples were above the threshold. Subsequently, the remain-
ing 40 poor-quality samples were prepared again, resulting in
the inclusion of 6 additional plasma samples. Likely, the 31
faulty samples contained no or very diluted plasma in the
liquid of the storage tube. Finally, 1542 (i.e. 1474 samples and
68 pools) acquisitions were included in the final dataset (2%
of samples were excluded, DiOGenes Precursor-level-Spec-
tronaut-Report.zip). The completeness of the full dataset was
74% at the protein level (Fig. 2E). Overall, on average 408
proteins were identified (supplemental Fig. S5B, and 317 pro-
teins were identified in 90% of the LC-MS DIA acquisitions
(supplemental Fig. S5C). The average CVs for all label-free
protein quantities was 52% across the 1474 samples (Fig. 2F),
ranging between 48 and 52% within the CIDs (Fig. 2G). CVs of
the protein quantities of individuals that donated blood sam-
ples at all four CIDs were lower than inter-individual CVs (23%
CV compared with 38%) (Fig. 2H).
Stable Isotope Standards in DIA—To explore and validate
the use of stable isotope standard (SIS) peptides-based
quantification, SIS were spiked into the DiOGenes sample set
and analyzed in combination with the label-free peptide li-
brary. As a result, all the SIS peptides could be detected with
16% missing values (Fig. 3A) or 90 of the 99 SIS peptides
could be detected in more than 90% of the LC-MS runs (Fig.
3B). The median of the CVs for the stable isotope standards
was calculated to be 19% (Fig. 3C). The endogenous peptides
ranged from 102–108 (normalized label-free intensity), the SIS
with an intensity in the upper half (105-108) were identified and
quantified without missing values (supplemental Fig. S6). Im-
portantly, 68 endogenous counterpart peptides could be de-
tected (73% data set completeness), the use of SIS enabled
the identification and quantification of 6% more endogenous
peptides counter parts. Importantly, PCA analysis of those
absolutely quantified endogenous peptides did not display
the previously identified batch effect (supplemental Fig. S7),
demonstrating a clear advantage of the isotopic labeling tech-
niques regarding quantification accuracy.
Plasma Proteome Characterization—In DiOGenes, the
plasma samples were collected in eight countries (centers).
Comparing the centers, two centers differed from the rest
(supplemental Fig. S8A), which was also previously observed
(Moreno et al.) (13). When we looked at hemolysis judged by
hemoglobin contamination of the plasma samples, we saw
FIG. 1. Capillary flow data-indepen-
dent acquisition plasma proteomics. A,
A plasma pool sample was acquired in ten
re-injections on the established capillary
flow DIA setup. The total identifications
and the identifications with CV below
10% or 20% were calculated. B, The CV
of each protein was calculated. C, The
reproducibility of protein identification
was analyzed by counting the repeated
identification of the individual proteins
across the 10 runs. D, Quantification re-
producibility of six plasma proteins span-
ning nearly six orders of magnitude
(ALB (serum albumin), HP (haptoglobin),
APOC3 (apolipoprotein C-III), PROS1 (vi-
tamin K-dependent protein S), F11 (coag-
ulation factor XI), and PI16 (Peptidase in-
hibitor 16)). E, The identification and
quantification of FDA approved biomark-
ers was assessed. 47 of 52 identified bio-
markers were quantified with CV below
20% (of a total of 109 described by An-
derson et al. (38)).
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clear differences between the centers indeed, but no correla-
tion to the centers was observed (supplemental Fig. S8B and
S8C), suggesting an overall low degree of contamination from
red blood cells in the plasma samples.
A statistical power analysis showed that for 21% of the
proteins a differential abundance of 10% could be detected
with  90% power (433 clinical samples, supplemental Fig.
S9). At the baseline (i.e. CID1), the proteins with the lowest
variability were involved in blood coagulation, whereas the
proteins with highest variability were involved in immune
response (supplemental Fig. S10), confirming the detection
of relevant biological information. Comparing 225 plasma
samples from males and 225 plasma samples from females
at baseline revealed clear differences between the genders
with 207 proteins significantly and differentially abundant.
These included the well-described pregnancy zone protein
(PZP, 3.6-fold higher in woman) and sex hormone binding glob-
ulin (SHBG, 1.6-fold higher in woman), which were among the
most significantly differentially abundant proteins. This obser-
vation agrees with previous studies (12, 21).
FIG. 2. Exploratory analysis of the
DiOGenes dataset. A, Design of the
European-wide weight loss and main-
tenance study called DiOGenes (http://
www.diogenes-eu.org). B, The 1508
samples and 68 pools were randomized
into 17 96-well plates for sample prepa-
ration and LC-MS acquisition. C, The
missing values for the 34 replicates of
the CID1-pool were calculated. D, The
CVs for proteins were calculated for
the 34 replicates of the CID1-pool. E,
The missing values for proteins of the
whole sample set of 1474 quality-con-
trolled DiOGenes samples was calcu-
lated. F, The CVs for proteins were cal-
culated for the full dataset. G, The CVs
for proteins were calculated for each
CID. H, For the analysis of intra individ-
ual CVs of proteins, only individuals who
were sampled at all 4 CIDs were consid-
ered and compared with inter individual
CVs.
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DiOGenes Biological Findings—Clustering of the data
showed that the weight loss time point (i.e. CID2) differed the
most from the baseline (i.e. CID1) and also the two weight
maintenance time points (i.e. CID3 and CID 4) (Fig. 4A, sup-
plemental Fig. S11). Using statistical inference of differential
abundance, 271 (102 with 10% change) proteins were sig-
nificantly different between CID1 and CID2, 151 (32 with
10% change) proteins between CID1 and CID3 (Fig. 4B,
supplemental Fig. S12) and 26 (14 with 10% change) be-
tween CID1 and CID4. Eighteen proteins shared altered ex-
pression in all time points compared with baseline (DiOGenes
Label-free t test results.xlsx and DiOGenes Protein Abun-
dance Boxplots.pdf).
All classes of clinically relevant apolipoproteins (20 in total)
were profiled in the dataset and all except one responded to
the weight loss and showed distinct expression profiles:
APOA remained largely unchanged. The levels of a group of
apolipoproteins first increased during weight loss and then
either increased further (APOD), remained high (APOA5,
APOM and APOF) or was reduced to initial levels (APOC2).
The levels of the second group were first reduced after weight
loss and then either surpassed the baseline levels during
weight maintenance (APOH, APOA1, APOA2, APOA4,
APOC1, CLUS), went back to initial levels (APOB, APOC3,
APOC4) or stayed at reduced levels (APOE, APOL1, SAA1,
SAA2, SAA4) (supplemental Fig. S13). Proteins of the mem-
brane attack complex of the complement system were tightly
correlated among each other, as were the levels of hemoglo-
bin complex members.
After weight loss, proteins of the acute phase response
indicated a reduction in low-grade inflammation (inhibitors
were up-regulated and markers were downregulated, e.g.
CRP, ORM2, SERPINA1 and SAA1 levels dropped and A1AT/
AACT increased). This agrees with previous findings in labs
and clinics, for example by Esser et al. (39). Protein pathway
analysis using IPA (40) indicated activated lipid metabolism
and increased concentrations of cholesterol and (tri)acylglyc-
erols. It also indicated that accumulation of lipids was re-
duced while secretion/efflux and transport were activated.
Finally, it indicated that the release of prostaglandins was
reduced and a reduced recruitment of mononuclear leuko-
cytes (Fig. 4C, supplemental Fig. S14).
In the weight maintenance phase, reduced concentrations,
secretion and release of fatty acids and lipopolysaccharides
were observed based on IPA analysis. Additionally, low grade
inflammation remained reduced (Fig. 4B, supplemental Fig.
S14). Eighteen proteins remained significantly differentially
abundant from baseline to the two weight maintenance time
points. They are involved in the complement system, the
chronic inflammatory process of atherosclerosis (supplemen-
tal Fig. S15). Specifically, [1] the adipokine adiponectin re-
mained elevated in weight maintenance, it is involved in the
control of fat metabolism and insulin sensitivity (41); [2] apo-
lipoprotein F remained elevated, it is an important regulator of
cholesterol transport, (42); [3] apolipoprotein C-II remained
below baseline, it plays an important role in lipoprotein me-
tabolism as an activator of lipoprotein lipase and is a com-
ponent of chylomicrons, very low-density lipoproteins, low-
density lipoproteins and high-density lipoproteins (43); [4]
vascular cell adhesion protein 1, which may play a pathophys-
iologic role both in immune responses and in leukocyte emi-
gration to sites of inflammation (44); [5] complement factor H
and properdin, which are regulators of the alternative pathway
of the complement system (45); [6] sex hormone binding
globulin, which regulates the plasma metabolic clearance rate
of steroid hormones by controlling their plasma concentration
(46); [7] glutathione peroxidase 3, which protects cells and
enzymes from oxidative damage and for which a link to obesity
was found (47, 48); [8] selenoprotein P, which is involved in the
extracellular antioxidant defense properties of selenium and
FIG. 3. Stable isotope standard reference peptides for absolute quantification in DIA. A, The missing values in the dataset for the SIS
peptides spiked into the 1508 samples of the DiOGenes sample set. B, Number of missing values for each SIS reference peptides was
calculated. 90 SIS were identified in 90% of the acquisitions. C, The CVs for the SIS reference peptides were calculated.
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linked metabolic diseases (49); [9] cartilage acidic protein 1,
which is a glycosylated extracellular matrix protein and linked to
colorectal cancer (50); [10] zinc-alpha-2-glycoprotein increased
over time, which stimulates lipid degradation in adipocytes (51)
and is a candidate therapeutic agent against obesity via induc-
tion of a brown fat-like phenotype in white adipocytes (52, 53).
We analyzed the proteins that significantly changed in
quantity between baseline and weight loss separately for
males and females (167 individuals each) and discovered an
overlap of only 64 proteins. The overlapping proteins showed
the same direction of regulation (supplemental Fig. S16). Still,
many proteins were significant in either females or males,
showing the importance and relevance of a gender-specific
approach in dietary interventions and further tailored person-
alized nutrition.
Consistency with Other Large-scale Proteomics Weight
Loss Studies—The DiOGenes plasma samples collected at
CID1 and CID3 were previously analyzed using the so-called
ASAP2 pipeline (21) and interpreted by Moreno et al. (13). In
their work, depletion of the 14 most abundant plasma proteins
was performed, followed by isobaric labeling for sample mul-
tiplexing and DDA acquisition in duplicates using a nano-flow
FIG. 4. Biological processes during weight loss and maintenance. A, PLS-DA analysis of the DiOGenes dataset. B, The proteins
significantly differentially expressed in the dataset were clustered in a heat map. The CID1 time point was set to zero. The annotated protein
legend was colored by biological function: (lipid metabolism/transport (green); acute phase response/inflammation (red); blood coagulation
(blue); steroid hormone transport/regulation (violet) angiogenesis (brown) and immune system components (yellow). C, IPA pathway analysis
of the weight loss and weight maintenance to baseline time point, significantly enriched pathways are shown. Orange indicates an activated
pathway, white no activity change and blue an inactivated pathway. A dot means no significant enrichment of the pathway.
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LC setup with 150 min gradient separation. Comparing this
previous report to the present study, 272 proteins were com-
monly identified. The results of the statistical comparison of
plasma protein changes between CID1 and CID3 were also
compared between both studies (Fig. 5A). Remarkably, 21
proteins identified to be significantly differentially abundant by
Moreno et al. (from a total of 38 proteins of which three were
not detected in this study) were also found to be significantly
differentially abundant with same directionality of change in
our study (except two with low fold changes below 10%). In
Fig. 5A, the slope of the curve was 1.03 (R2  0.8798),
confirming agreement in the quantitative determination of pro-
teins and good performances of MS-based discovery pro-
teomics (note that plasma sample proteomic measurements
were separated by about three years). When looking only at
the proteins that changed by more than 10%, all commonly
identified proteins were significantly changed in both studies.
Insulin-like growth factor binding protein 2 (IBP2) was not
detected as significantly changed in our study, but insulin-like
growth factor 1 (IGF1) was, to which it binds with high affinity
(54).
Additionally, we compared the proteomic results of our
study to an unrelated weight loss study analyzed by Geyer et
al. (22). There, the same 8 weeks of caloric restriction was
performed. Importantly, when comparing significant differen-
tial abundances between baseline (e.g. CID1 in DiOGenes)
and weight loss (e.g. CID2 in DiOGenes), a large overlap of 53
proteins was found and the directions of change were con-
served (Fig. 5B). Here, the slope of the scatter plot was 0.44,
possibly because of the different samples analyzed in the
studies, but an R2 of 0.89 confirmed the very strong agree-
ment and robustness of biological findings.
Glycation Changes of Plasma Proteins—Using DIA, it is
possible to interrogate the raw data with different foci. There-
fore, DDA of the plasma pools were searched for post trans-
lational modifications of peptides (see methods). This re-
vealed a multitude of modifications (see DiOGenes Plasma
Modifications.xlsx). We decided to focus non-enzymatic gly-
cation of proteins by glucose which is biologically relevant in
the context of obesity and type 2 diabetes. The global PTM
analysis indicated that multiple amino acids were glycated.
We searched for N-linked glycation on lysine, arginine and the
protein N terminus (55) using a classical database search.
This resulted in a library containing 242 glycation sites on 70
proteins (listed in DiOGenes Plasma Glycation Sites.xlsx). 28
of these proteins were previously reported by Zhang et al.
(55). The most glycation sites were detected on serum albu-
min (36 sites), serotransferrin (13) and immunoglobulin kappa
constant region (7).
Applying this library to the DiOGenes DIA resulted in the
identification and quantification of 234 glycation sites. Sur-
prisingly, global unsupervised clustering analysis revealed
that CID4 clustered away from the first three other CIDs (Fig.
6A). Interestingly, this contrasts with the clustering based on
whole protein expression. 16 proteins showed significantly
altered states for glycation in the dataset (Fig. 6B, see file
DiOGenes Plasma Glycation t test Result.xlsx). All glycation
sites on albumin were slightly elevated after the weight loss
period.
DISCUSSION
We established a robust and sensitive MS proteomic work-
flow based on capillary flow, single-shot DIA, applicable to
large-scale clinical research studies. We profiled a clinical
FIG. 5. Comparison of biological findings to related large-scale proteomic weight loss maintenance studies. A, The significantly
differentially abundant proteins in this study resulting from the CID3 to CID1 comparison (151 candidate proteins) were compared with the
candidate list published by Moreno et al. (13) (32 candidate proteins) using the same DiOGenes samples of CID1 and CID3, but analyzing them
with the ASAP2 pipeline including depletion, isobaric labeling, and DDA acquisition with an Orbitrap Elite mass spectrometer. B, Comparison
of the significantly differentially abundant proteins between CID2 and CID1 resulting from this study (from 271 candidate proteins) to the results
from the independent weight loss study by Geyer et al. (22) with the same layout of 8 weeks of weight loss (from 68 candidate proteins),
acquired with a Q Exactive HF mass spectrometer.
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sample set of 1508 samples of the weight loss and mainte-
nance study DiOGenes at a depth of 565 proteins. This is
enough to cover the clinically relevant lipoproteins (20 in total)
and markers of inflammation, as well as many other important
functional blood proteins. The entire workflow demonstrated
the high consistency demonstrated by control pools with high
reproducibility (92% completeness) and low variance (10%
CV) spread across the 1576 samples (Fig. 2). For 32 of the 72
samples with low protein identifications, a reinjection in-
creased the number of identifications above the quality
threshold (i.e. 330 proteins). No “cross reactivity” exists in
MS, like with antibodies-based approaches and no MS1
alignment had to be performed. This enabled detection of
significant changes of protein levels below 10%. Hence, this
resulted in more proteins being detected as significantly, dif-
ferentially abundant as compared with similar studies (13, 22).
A large-scale proteomics experiment with hundreds of
samples needs proper planning. These include sample stor-
age and handling, e.g. for randomization of samples or intro-
duction of quality control pools to track the performance of
the proteomic workflow (at both sample preparation and
LC-MS acquisition levels). The sample preparation and
LC-MS were controlled with pools on each of the 96-well
plates. The data analysis requires a software able to process
and analyze the whole project to ensure proper FDR control,
protein quantities and normalization. Statistical testing also
needs to be selected correctly to address potential confound-
ing biological variables (e.g. more females in a condition, age
differences or effects of sample collection at multiple centers).
The wide-ranging differences that were detected in the
female and male human plasma proteomes at baseline dem-
onstrate the importance of considering these observations in
a plasma proteomics experiment and considering those po-
tential confounders. It can also serve to control the quality of
the data using gender, as is regularly performed in the field of
genomics (56). Additionally, effects from collection centers
(here, in different countries) including genetic background,
different diets, environment and blood drawing effects could
confound biologically relevant findings. Additionally, protein
variance across the study was smaller within an individual
than between individuals (Fig. 2D), a finding that has been
previously observed (22). The sampling of individuals at mul-
tiple points of intervention enabled paired statistical tests with
the use of unequal cohorts from different centers/genders,
keeping statistical power high.
Weight loss and maintenance triggered multiple changes in
biological pathways including sustained reduction of low-
grade inflammation and the activation of lipid metabolism.
FIG. 6. Non-enzymatic glycation analysis of plasma proteins. A library was generated containing high quality glycation sites and was then
applied to the targeted analysis of the DIA DiOGenes dataset. A, All identified glycation sites changes were calculated comparing to CID1 and
corrected by the protein abundance change. Subsequently, the data was visualized in a clustered heat map (HC, average linkage). B, The
glycation sites significantly differentially abundant in the dataset were processed as described above.
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These findings were confirmed in an independent weight loss
study (22). The sustained reduction of apolipoprotein E dem-
onstrated a positive effect on cardiovascular risk (57).
An unbiased search for PTM modifications revealed a mul-
titude of variations. DIA enabled the comprehensive profiling
of 234 glycation sites, for the first time, without the need for
enrichment in the samples for glycated moieties. Globally,
glycation was observed to increase first, during weight loss, to
then drop during the weight maintenance phase to levels
below those at baseline. There appears to be a delay in the
glycation change post-weight loss. This reduction indicates
potential beneficial effects, because glycated proteins are
known to trigger an immune system response (58). A glycated
protein is considered by the immunological system as an
“undesired” species, and consequently its enzymatic diges-
tion is activated (58) e.g. glycated albumin in diabetes (59).
The size of the data set also enabled analysis of subgroups
and differences, e.g. the number of significantly differentially
abundant proteins after weight loss was different for men and
women. Similar analyses can be performed for centers, diets,
ages and BMIs in future investigations.
The robustness of the findings from large-scale proteomics
experiments with plasma could be clearly demonstrated in
two independent ways by comparison: (1) to the works of
Cominetti et al. (21) and Moreno et al. (13) which used the
same plasma samples from the DiOGenes study, but per-
formed depletion and isobaric labeling before MS acquisition
and (2) to the results of the analysis of another weight loss
study (60), acquired with label-free DDA by Geyer et al. (22).
These comparisons show that the results of large-scale pro-
teomics experiments are technically and biologically repro-
ducible and can be generalized (Fig. 5).
In contrast to Cominetti et al., in this study no depletion and
labeling costs were accumulated and no repeated injections
were necessary. The time spent per sample in this study was
half that spent by Cominetti et al. (Cominetti et al. used an older
generation Orbitrap Elite Hybrid Ion Trap Orbitrap, whereas we
used an Orbitrap Fusion Lumos Tribrid mass spectrometer) and
5.2 times less than Geyer et al. (Geyer et al. used a Q Exactive
HF Quadrupole Orbitrap). (supplemental Table S4). Because of
the higher coverage and/or reproducibility, this study was more
sensitive in identifying differential abundances (e.g. 2.9-fold
more for CID3/CID1 than Moreno et al. and 60% more than
Geyer et al. (for weight loss/baseline) at equal LC-MS time.
SIS-based absolute quantification enables additional post-
analysis strategies relying on absolute quantities (pathway
models, kinetic models, among others). We showed, that SIS
are reproducibly identified, if the SIS are spiked in at an
intensity corresponding to the upper half of the label-free
intensity range of plasma (Fig. 3). Importantly, batch effects
generated by the LC and MS did not propagate into the
directly, quantified proteins by SIS. Therefore, quantifying the
absolute amount of most proteins has the potential to improve
the homogeneity of large extended projects and the ability to
compare different projects. This is reasonable, because in
plasma 300 to 1000 proteins are routinely detected. To reduce
batch effects arising from differential sample preparation, ad-
dition of known amounts of labeled proteins to native plasma
would be the ideal solution (61).
Based on the herein demonstrated efficiency of the large-
scale proteomic workflow and the recent evolution of large-
scale plasma proteomics, we conclude that the tools are now
in place to engage in biomarker discovery. This opens the use
of approaches such as capillary flow DIA or the recently
introduced Evosep liquid chromatographic system (62) to
boost the discovery of new biomarkers, a prerequisite in
personalized medicine and nutrition.
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